Recent progress in computational design and structural analysis allows reverse engineering of biologically active antigens from broadly neutralizing antibodies.

We are currently operating under an exclusive research and licensing agreement with the Scripps Research Institute and the University of Washington in our field of activities. Our research applies in silico computational design and in vitro directed evolution to the design and optimization of antigens and broadly neutralizing antibodies.